Help protect
your patients

View head-to-head data

Starting patients on APRETUDE



Shield icon with upward arrow Shield icon with upward arrow

Efficacy and safety evaluated in two large-scale head-to-head clinical trials with the most diverse patient populations in HIV prevention trials to date1,2


Shield icon with star Shield icon with star

Superior efficacy versus a daily
demonstrated in two
clinical trials1,2*

  • >3X reduction in HIV-1 incidence in HPTN 083 (cisgender men
    and transgender women): HR
    0.31 (95% CI: 0.16 -0.58;
  • 12X reduction in HIV-1 incidence in HPTN 084 (cisgender
    women): HR 0.10 (95% CI: 0.04-0.27); P<0.0001


Shield icon with checkmark Shield icon with checkmark

Two months of continuous HIV protection with each injection
(after two initiation doses)§


HPTN 083 (N=4566) and HPTN 084 (N=3244) were randomized, double-blind, controlled trials evaluating the safety and efficacy of APRETUDE every 2 months vs daily oral TRUVADA for HIV-1 prevention in adults at risk of acquiring HIV-1. The primary endpoint of both studies was the rate of incident HIV-1 infections.


Incident HIV-1 infections: TDF/FTC: 39 in 3193 person-years (1.22/100 person-years) and APRETUDE: 12 in 3211 person-years (0.37/100 person-years).


Incident HIV-1 infections: TDF/FTC: 36 in 1946 person-years (1.85/100 person-years) and APRETUDE: 3 in 1960 person-years (0.15/100 person-years).


§Administered as an intramuscular injection by a healthcare professional every 2 months after 2 initiation injections administered 1 month apart. Adherence to the dosing schedule is strongly recommended. 

CI=confidence interval; HPTN=HIV Prevention Trials Network; HR=hazard ratio; TDF/FTC=tenofovir disoproxil fumarate/emtricitabine.

Headshot of bald Black man in his 30s, smiling, wearing a maroon blazer, on a green background

See which PrEP option patients chose in the open-label extension phase of the APRETUDE clinical trials.

See patient choice data

Photo portrait of three young people, on a purple background, featuring a Black man on the left, Black woman on the right, and a Latino man in the middle

Real people.
Real experiences.
Watch stories from
real people on APRETUDE.

Watch videos

Not actual patients.

Headshot of a White man with a beard in his 30s, looking straight ahead, on a green background

Information and resources to help your patients start APRETUDE.

Access and support



  1. Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women.
N Engl J Med. 2021;385(7):595-608. doi:10.1056/NEJMoa2101016

  2. Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779-1789. doi:10.1016/S0140-6736(22)00538-4